2012-09-20 13:53:11 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to China Chemical and Pharmaceutical Co Ltd and produced a Rating Update Report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering China Chemical and Pharmaceutical Co Ltd (1701). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential China Chemical and Pharmaceutical Co Ltd investor.
Report Summary: China Chemical and Pharmaceutical Co Ltd is a low quality company with a neutral outlook. China Chemical and Pharmaceutical Co Ltd has strong business growth and is run by passable management. The trend in China Chemical and Pharmaceutical Co Ltd fair value exchange rate against its closest rated-competitor, Yung Shin Pharma Ind. Co. Ltd, has been depreciating over the past 2 weeks. When compared to its closest competitor, China Chemical and Pharmaceutical Co Ltd
shows greater overvaluation and is equally likely to underperform the market.
The 3-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of China Chemical and Pharmaceutical Co Ltd for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.